Company Overview: BLUE

Upcoming Projects (BLUE)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (BLUE)

Key Takeaways from ASH 2021: A conversation with a hematologist attending the conference
Tickers: SNY, IBB, BLUE, QURE
Executed On: Dec 13, 2021 at 02:30 PM EST

Expired Projects (BLUE)

An in-depth look at the Gene Therapy Landscape
Tickers: VRTX, BLUE, ONCE, CRSP, EDIT, NTLA
Execute By: Dec 31, 2021
Digging into Bluebird’s bb21217 P1 in treating Multiple Myeloma
Ticker: BLUE
Execute By: Mar 06, 2020

Upcoming & Overdue Catalysts (BLUE)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (BLUE)

FDA has placed Bluebird bio's (BLUE) studies of elivaldogene autotemcel (eli-cel, Lenti-D) for cerebral adrenoleukodystrophy (CALD) on clinical hold following safety report
Ticker: BLUE
Occurred on: Aug 09, 2021
bluebird bio's (BLUE) Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel bb2121 - KarMMa) in Relapsed/refractory multiple myeloma PDUFA date set for March 27, 2021
Ticker: BLUE
Occurred on: Mar 26, 2021
Bluebird Bio's(BLUE) Phase 3 data of LentiGlobin - HGB-212 Northstar-3 in TDT and the β0/β0genotype to be presented at EHA
Ticker: BLUE
Occurred on: Jun 14, 2019
Bluebird Bio (BLUE) to complete Phase 2/3 Study of Hematopoietic Stem Cells Transduced with Lenti-D Lentiviral Vector for the treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD) in second half of 2018
Ticker: BLUE
Occurred on: Sep 05, 2018
Bluebird Bio (BLUE) to complete Phase 1/2 study of LentiGlobin BB305 to subjects with beta-thalassemia major or severe sickle cell disease in December 2017
Ticker: BLUE
Occurred on: Dec 10, 2017
Bluebird Bio (BLUE) to finish Phase 1/2 study of LentiGlobin® BB305 in Beta-Thalassemia Major Subjects in September 2017
Ticker: BLUE
Occurred on: Dec 10, 2017
Phase 1/2 trial updated data of LentiGlobin for β-Thalassemia and Sickle Disease expected at ASH December 2016
Ticker: BLUE
Occurred on: Dec 05, 2016
BlueBird Bio's (BLUE) LentiGlobin for Transfusion-Dependent Beta Thalassemia Granted PRIME Status by EMA
Ticker: BLUE
Occurred on: Sep 21, 2016
FDA has removed the clinical hold on the Phase II clinical trial of JCAR015 (known as the “ROCKET” trial) in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL)
Tickers: JUNO, CLLS, KITE, BLUE, ZIOP
Occurred on: Jul 12, 2016
Bluebird Bio (BLUE) to present interim data from Starbeam Study of Lenti-D for its effectiveness in treating cerebral adrenoleukodystrophy at the American Academy of Neurology (AAN) 2016
Ticker: BLUE
Occurred on: Apr 20, 2016
Bluebird Bio (BLUE) will present data from the ongoing Phase 2/3 Starbeam Study (ALD-102) for the treatment of cerebral adrenoleukodystrophy (CALD) at the American Academy of Neurology (AAN) 2016 Annual Meeting
Ticker: BLUE
Occurred on: Apr 20, 2016
Bluebird Bio (BLUE) CFO to resign, replaced by COO
Ticker: BLUE
Occurred on: Mar 18, 2016
Leukemia Research presented at American Association for the Advancement of Science (AAAS) leads to boost for CAR-T developers
Tickers: BLUE, KITE, CLLS, ZIOP, JUNO, BLCM, CYAD, ADAP
Occurred on: Feb 16, 2016

Strategic Initiatives (BLUE)

Bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy
Ticker: BLUE
Announcement Date: Dec 07, 2017

BLUE Overview